Corporate/Mergers & Acquisitions specialist, encompassing domestic, regional and cross-border private and public takeovers and mergers and acquisitions, pre-transaction M&A strategies, corporate commercial work, corporate finance, corporate restructurings (solvent and insolvent), securities law, private equity and general corporate law. Ranked in Asialaw and Chambers. Independent Director, Hyphens Pharma International.

• Advised FMC Corporation on the Singapore corporate aspects of the two transformative global transactions with DuPont involving 45 countries and a consideration of US$1.6 billion.
• Acting for Yinson Eden Pte. Ltd., an indirect wholly-owned subsidiary of Yinson Holdings Berhad,  in its proposed acquisition of up to US$916 million of Ezion Holdings Limited’s existing bank loan which may result in Yinson Eden holding over 85% of the enlarged share capital of Ezion.
• Advised Standard Chartered Private Equity (Singapore) Pte. Ltd. in its joint venture with certain majority shareholders of SGX-ST-listed Tat Hong Holdings Ltd to privatiseTat Hong Holdings Ltd.
• Acted for GlobalFoundries Singapore Pte. Ltd. in the sale of its FAB 3E in Singapore to Vanguard International Semiconductor Corporation for US$236 million.

• M&A
• Private equity

• Financial services
• Food and beverage
• Healthcare
• Industrials
• Tech and telecoms

• Singapore
• Malaysia
• England and Wales

• The Law Society of Singapore
• Singapore Academy of Law

• LLB (Hons), National University of Singapore, (1989)
• LLM, National University of Singapore, (1995)